Emmaus Life Sciences, Inc. Appoints Willis C. Lee as Chief Financial Officer
October 08, 2016 at 02:10 am IST
Share
On October 3, 2016, Emmaus Life Sciences, Inc. appointed Willis C. Lee as Chief Financial Officer, effective immediately. Mr. Willis Lee succeeds Steve Lee, who has served as the company's Interim Chief Financial Officer since April 29, 2016. Steve Lee will continue in his prior role as an independent consultant to the company. Mr. Willis Lee has served as Chief Operating Officer since May 2011, as a director since December 2015, and as Vice-Chairman of the Board of Directors since January 2016. He will continue to serve in these roles.
Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery, development, marketing, and sale of treatments and therapies, primarily for rare and orphan diseases. The Companyâs lead product, Endari (prescription-grade L-glutamine oral powder), helps to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients aged five years and older. Its product pipeline includes ELS001/ELS007, ELS004, ELS005, ELS003, and ELS002. The Company, through Kainos Medicine, Inc. (Kainos), has a license in the territory encompassing the United States, the United Kingdom, and the European Union to patent rights, know-how, and other intellectual property relating to Kainosâs IRAK4 inhibitor, referred to as KM10544, for the treatment of cancers, including leukemia, lymphoma, and solid tumor cancers. It has also developed chondrocyte and osteoblast cell sheets using human mesenchymal stem cells.
EMMAUS LIFE SCIENCES, INC. 
